Marco Meglio

Cranbury

Editor at NeurologyLive

Host at NeurologyLive Mind Moments

Editor, @Neurology_Live 🧠| Hofstra Alum | Views are my own | 📧[email protected] | bagel and basketball enthusiast

Featured in: Favicon

neurologylive.com Favicon

neurologytimes.com Favicon

hcplive.com Favicon

newsbreak.com Favicon

ajmc.com

contemporaryobgyn.net Favicon

diagnosticimaging.com Favicon

managedhealthcareexecutive.com Favicon

patientcareonline.com Favicon

msviews.org + 3 more

Articles

NeurologyLive® Brain Games: May 11, 2025

4 days ago | neurologylive.com | Marco Meglio

Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data

5 days ago | neurologylive.com | Marco Meglio

Newly announced findings from the phase 2 MAGNIFY trial (NCT05893537) showed that treatment with investigation zervimesine (Cognition Therapeutics), a small molecule agent, led to slower lesion growth in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) over an 18-month period.1 In the latest data update, patients on 200 mg of once-daily zervimesine, or CT1812, had 28.6% slower GA lesion growth on average when compared with those on placebo,...
Long-Term Extension Highlights Sustained Therapeutic Benefits of Fenfluramine

6 days ago | neurologylive.com | Marco Meglio

Recently published findings from an open-label extension (OLE; NCT02823145) study highlighted the therapeutic benefits and safety profile of fenfluramine (Fintepla; UCB) in patients with Dravet syndrome (DS) over a 3.5-year period.
Muscle MRI May Serve as Sensitive Biomarker for ALS Disease Progression

1 week ago | neurologylive.com | Marco Meglio

In a recently published small-scale study, findings showed that longitudinal quantitative MRI reliably detects progressive atrophy and decrease of functional rest muscle area in patients with amyotrophic lateral sclerosis (ALS), which correlated with progressive loss of muscle strength and global disease progression.
Subthalamic Focused Ultrasound Outperforms Ventral Intermediate Thalamotomy in Sustained Parkinson Disease Tremor Control

1 week ago | neurologylive.com | Marco Meglio

In a comparative, 2-center study of patients with Parkinson disease (PD) with medication-refractory tremor, results revealed that both unilateral focused ultrasound ventral intermediate thalamotomy (Vim-FUS) and subthalamic nucleus FUS (STN-FUS) are effective options; however, the effects of STN-FUS lasted longer.
Case Report Highlights Rare Case of Progressive Multifocal Leukoencephalopathy in Childhood NMOSD

1 week ago | neurologylive.com | Marco Meglio

Recently published in the Multiple Sclerosis Journal, investigators reported the first pediatric and fatal case of progressive multifocal leukoencephalopathy (PML) in a child with neuromyelitis optica spectrum disorder (NMOSD) 9 years after his initial diagnosis. The study authors concluded that while although rare, PML should be considered in patients with NMOSD receiving rituximab, especially in cases of protracted relapse presentations with atypical radiological findings.
MDA Ambassador Sunny Brous: Progress, Advocacy, and Connection in ALS

1 week ago | neurologylive.com | Marco Meglio

Amyotrophic lateral sclerosis (ALS) is a rare but devastating neurodegenerative disease that affects approximately 1-2 per 100,000 people globally. Despite its relatively low prevalence, ALS has garnered significant attention in recent years due to advances in research and therapeutics. Notable breakthroughs include FDA approval of drugs like edaravone (Radicava; MT Pharma) and tofersen (Qalsody; Biogen), the first marketed treatment specific for those with SOD1 mutations.
Huntington Drug PTC518 Meets Primary End Point in Phase 2 Study

1 week ago | neurologylive.com | Marco Meglio

According to a new announcement from PTC Therapeutics, investigational PTC518 met its primary end point in the phase 2 PIVOT-HD study (NCT05358717), with results showing a statistically significant change in blood Huntingtin (HTT) protein levels over a 12-month period and promising 24-month data as well.
Crossover Trial Highlights Therapeutic Benefit of Daridorexant in Chronic Insomnia and Comorbid Nocturia

1 week ago | neurologylive.com | Marco Meglio

Daridorexant (Quviviq; Idorsia), an FDA-approved medication for insomnia, was recently shown to improve subjective sleep and nocturia symptoms while decreasing daytime impairment in patients with chronic insomnia and nocturia.
Nexalin Initiates Q-Submission Process for Transcranial Alternating Current Stimulation Device in Alzheimer Studies

1 week ago | neurologylive.com | Marco Meglio

Following positive conversations with the FDA, Nexalin plans to submit a Q-Submission to the agency for its Gen-2 SYNC system, a non-invasive neuromodulation device that does not require anesthesia or sedation.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 679
Tweets: 3K
DMs Open: No

Marco Meglio @marcomeglio1

9 May 25

RT @LEAD_Coalition: #DownSyndrome and #Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress https://t.co/jL7ZTpz6Ih by @marc…

Marco Meglio @marcomeglio1

8 May 25

RT @RichaSharmaMD: Happy to share our review article about acute stroke therapeutics! https://t.co/tB4sGAAQ8e

Marco Meglio @marcomeglio1

5 May 25

RT @AUPN_leaders: In the final video of our Elevating Women in #Neurology series with @neurology_live, Drs. Marie Eugene, Vanessa Hinson, &…

Marco Meglio

Articles

NeurologyLive® Brain Games: May 11, 2025

Zervimesine Robustly Slows Geographic Atrophy Lesion Growth in Latest Phase 2 MAGNIFY Data

Long-Term Extension Highlights Sustained Therapeutic Benefits of Fenfluramine

Muscle MRI May Serve as Sensitive Biomarker for ALS Disease Progression

Subthalamic Focused Ultrasound Outperforms Ventral Intermediate Thalamotomy in Sustained Parkinson Disease Tremor Control

Case Report Highlights Rare Case of Progressive Multifocal Leukoencephalopathy in Childhood NMOSD

MDA Ambassador Sunny Brous: Progress, Advocacy, and Connection in ALS

Huntington Drug PTC518 Meets Primary End Point in Phase 2 Study

Crossover Trial Highlights Therapeutic Benefit of Daridorexant in Chronic Insomnia and Comorbid Nocturia

Nexalin Initiates Q-Submission Process for Transcranial Alternating Current Stimulation Device in Alzheimer Studies

Contact details

Emails

Socials & Sites

X (formerly Twitter)